Basic HIV Vaccine Discovery Research (R01)

archived

Purpose. The aim of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to stimulate the discovery of an effective prophylactic HIV-1 vaccine by soliciting Research Project Grant (R01) applications for hypothesis-driven basic research in HIV/AIDS, and general virology and immunology focused on that aim. The emphasis is on discovery, including the identification of new concepts and approaches that will inform the design of an optimal prophylactic HIV-1 vaccine, or the implementation of applicable concepts and/or approaches that have been employed successfully in the development of vaccines for other infections. Mechanism of Support. This FOA will utilize the NIH Research Project R01 grant mechanism. This FOA will utilize the NIH Research Project R01 grant mechanism, and runs in parallel with FOAs of similar scope, including PA-06-519 Phased Innovation Awards (PIA) in AIDS Vaccine Research and PAR-06-285 HIVRAD that solicit applications under the R21/R33 and P01 mechanisms, respectively. Funds Available and Anticipated Number of Awards. NIAID intends to commit approximately $10M in total costs in FY 2010 to fund 15-25 applications submitted in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High